Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-02-09		NCT04639986

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Gilead Sciences	180

43 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Tumor Hospital of Xinjiang Medical University	Ürümqi	China	4
Ajou University Hospital	Suwon	South Korea	31
Anhui Provincial Hospital	Hefei	China	34
Asan Medical Center	Seoul	South Korea	131
Cancer Hospital Chinese Academy of Medical Science	Beijing	China	5
Chang Gung Memorial Hospital, Linkou	Taoyuan	Taiwan	8
Changhua Christian Medical Foundation Changhua Christian Hospital	Changhua	Taiwan	1
China Medical University Hospital	Taichung	Taiwan	54
Chinese PLA General Hospital	Beijing	China	39
Chongqing University Cancer Hospital	Chengdu	China	1
Dong-A University Hospital	Busan	South Korea	20
Fujian Medical University Union Hospital	Fuzhou	China	20
Guangdong Provincial People's Hospital	Guangzhou	China	37
Henan Cancer Hospital	Zhengzhou	China	60
Hubei Cancer Hospital	Wuhan	China	23
Jiangsu Province Hospital	Nanjing	China	39
Jilin Cancer Hospital	Changchun	China	15
Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung City	Taiwan	48
Korea University ANAM Hospital	Seoul	South Korea	56
Linyi Cancer Hospital	Linyi	China	19
Nanjing Drum Tower Hospital	Nanjing	China	24
National Cheng Kung University Hospital	Tainan	Taiwan	53
National Taiwan University Hospital	Taipei	Taiwan	203
Peking University People's Hospital	Beijing	China	68
Samsung Medical Center	Seoul	South Korea	170

Clinical trials